



GDUFA III Impact on DMF Assessment

Jayani Perera, Ph.D.

Senior Chemist, Division of Lifecycle API (DLAPI), Office of
Pharmaceutical Quality (OPQ)
CDER | US FDA

SBIA Generic Drug Forum – April 12-13, 2023

Overview



GDUFA III DMF enhancements:


- High level implementation processes
- Data
- Key points
- Some key take aways for Prior Assessment process

Assessment of DMF Solicited Off-cycle Amendments

Background

- Under GDUFA I & II, solicited DMF amendments were not picked up for assessment when there was no open ANDA review cycle
- Under GDUFA III, FDA will assess solicited DMF amendments related to original ANDAs and PASs upon receipt even if the original ANDA or PAS in which the DMF is referenced is not currently under assessment
 - Priority will be given to the amendments related to ANDAs for which acceptability of the DMF assessment may result in an approval

High Level Implementation Process: Solicited Off-Cycle Review



Impact on DMF Assessment

- Have an opportunity to do earlier assessment and leverage “off-cycle” time to get the DMF to an adequate status more quickly
- This should improve the number of approvals and reduce total number of cycles and time to approval
- We estimate between 70 to 100 solicited off-cycle amendments will be prioritized and reviewed annually under this enhancement

Solicited Off-cycle Process Data



From 10/01/2022 to 3/22/2023

- Total number of solicited amendment received: 170 (off-cycle and on-cycle)
- Number triaged as off-cycle: 89
- Number prioritized and assigned for off-cycle assessment: 36

Key Points

- Solicited amendments are triaged within a week of receipt
- Solicited off-cycle amendments that are prioritized under GIII are assigned for review with a 120 day DMF review target date (DTD)
- The DTD is communicated to the DMF holder/agent via email
- No email is sent unless the solicited amendment is prioritized

Key Points Cont.

- Changes in the assigned DTD:
 - If a referencing application opens a review cycle requiring an earlier DTD consistent with the application goal date, the DTD adjusted to the earlier date
 - Submission of an unsolicited amendment after the off-cycle assignment may result in an extension to the DTD at FDA discretion.
- If a referencing application opens a review cycle requiring a later DTD consistent with the application goal date, the off-cycle amendment will retain the current DTD



DMF Review Prior to ANDA Submission

What are Prior Assessments?




- Review of Drug Master Files (DMFs) before the receipt of an ANDA or its amendments:
 - Request should be submitted 6 months prior to the ANDA's planned submission date
 - Review request is submitted by the DMF holder
 - Available to newly submitted DMFs and previously unreviewed DMFs
 - Certain conditions should be met as stated in GIII Commitment Letter

What are Prior Assessments?




- Request for assessment for a PAS to add a new API source:
 - PAS is for a drug product that could help mitigate or resolve a drug shortage
 - PAS is for a drug product that could help address a public health emergency

High Level Implementation Process: DMF Prior Assessment



GIII Timeline: Prior Assessments



* Suggested communication points between DMF and ANDA

Impact on DMF Assessment

- Have an opportunity to assess a DMF outside of an application
- The longer review clock allows multiple DMF assessment cycles before the end of GDUFA clock
- The goal is to get the DMF to an adequate status as quickly as possible to reduce the number of assessment cycles for ANDAs and facilitating timely access to generic drugs for the patients
- Estimate about 80 original DMFs might be qualified under the Prior Assessment enhancement each year

Prior Assessment Process Data



from 10/01/2022 to 3/22/2023

- Total number of Prior Assessment requests received: 4
- Number granted: 2
- Number denied: 2

Key Points



- Prior Assessment requests are triaged upon receipt
- Gives industry a chance to fix the request by issuing an Information Request (IR)
- Grant or deny letter issued to the industry within 2 weeks
- If denied, a reason for denial will be communicated
- When granted, DMF review target date (DTD) is communicated to the industry

Prior Assessments: Drug Shortage and Public Health Emergency Product Criteria



- Applicants should take advantage of prior assessment when adding a new API source for a drug shortage prior approval supplement (PAS)
- For drug shortage or public health emergency products, the DMF holders can include a request to waive 6 month condition in the cover letter when unable to submit the request 6 months in advance

Planning Ahead



- DMF holders should communicate with their customers (applicants) before submitting a prior assessment request
- Follow the draft guidance when submitting a prior assessment request
- Email DMFOGD@FDA.HHS.GOV mailbox with any questions

Summary



- GIII DMF enhancements allow for assessment of DMFs outside of an application
- Under prior assessment, communication between DMF holder and ANDA applicant is essential
- Prior assessment draft guidance has all the details for successful submission of a prior assessment request
- Refer to the SBIA DMF Workshop on November 30, 2022

Resources



- GDUFA III Commitment Letter: <https://www.fda.gov/media/153631/download>
- Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA, Guidance for Industry, Draft Guidance: <https://www.fda.gov/media/162019/download>
- GDUFA II Drug Master Files (DMFs): <https://www.fda.gov/drugs/forms-submission-requirements/gdufa-ii-drug-master-files-dmfs>
- GDUFA III Drug Master File (DMF) Review Enhancements:
<https://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iii-drug-master-file-dmf-review-enhancements>
- SBIA DMF Workshop: GDUFA III Enhancements and Structured Data Submissions:
Session 1: <https://www.youtube.com/watch?v=ECM1A1UCFcQ>
Session 2: https://www.youtube.com/watch?v=8_9nOzMNebk

Acknowledgements



- CDR. Dave Skanchy
- Erin Skoda
- Jennifer Nguyen
- CDER SBIA